The demand for transparency when looking at the relationship between life science manufacturers and health care providers is at an all-time high. Recent updates to the Physicians Payments Sunshine Act will increase the scope of responsibilities for manufacturers and HCPs alike.
The current landscape surrounding aggregate spend and the open payments system also involves the discussion of conflicts of interest, ethical interactions, and federal enforcement.
Interactions with HCPs can provide tremendous value to life science manufacturers but also presents risks for provider disputes or legal violations. Enforcement in the industry is constantly evolving on state, federal and global levels.
With differences in reporting requirements, it is up to manufacturers to manage risk, maintain transparency and ensure compliance at all times, which can be extremely difficult. ExL Events is proud to bring you the 10th Aggregate Spend and Open Payments Conference.
Over the past nine years, we have had the privilege of educating over 223 organizations and will continue to provide thought-provoking sessions, interactive panels, and spotlight sessions this year.
Source: Event Website